Stockreport

Lisata Therapeutics Announces Mutual Termination of License Agreement with Qilu Pharmaceutical for Certepetide

Lisata Therapeutics, Inc.  (LSTA) 
PDF BASKING RIDGE, N.J., Jan. 27, 2026 (GLOBE NEWSWIRE) -- Lisata Therapeutics, Inc. (Nasdaq: LSTA) (“Lisata” or the “Company”), a clinical-stage pharmaceutical company de [Read more]